Phamaceutical trade lobby responds to Brexit deal
The Association of the British Pharmaceutical Industry (ABPI) has responded to Theresa May’s Brexit deal, after the government announced a 585 page draft withdrawal agreement has been agreed to by both the United Kingdom and the European Union.
However both the British and EU parliaments will now have to ratify the agreement. The news has already led to the resignation of Brexit Secretary Dominic Raab and Secretary of State for work and pensions, Esther McVey.
Mike Thompson, CEO at the Association of the British Pharmaceutical Industry (ABPI), said: “We welcome this important step towards securing a Brexit deal. Agreeing a transition period will mean that our members can continue to supply medicines to patients without delay or disruption come March 2019.”
“There’s much to build on. But there’s more work to be done. We are committed to working with the UK and the EU so that close cooperation on scientific research and medicines regulation are central to a future partnership agreement for the benefit of all.”
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …